FI885361A0 - Laekemedel-monoklonala antikroppskonjugat. - Google Patents

Laekemedel-monoklonala antikroppskonjugat.

Info

Publication number
FI885361A0
FI885361A0 FI885361A FI885361A FI885361A0 FI 885361 A0 FI885361 A0 FI 885361A0 FI 885361 A FI885361 A FI 885361A FI 885361 A FI885361 A FI 885361A FI 885361 A0 FI885361 A0 FI 885361A0
Authority
FI
Finland
Prior art keywords
anticropps
conjugated
ceiling model
drug
model monoclonal
Prior art date
Application number
FI885361A
Other languages
English (en)
Other versions
FI885361A (fi
Inventor
Peter D Senter
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of FI885361A0 publication Critical patent/FI885361A0/fi
Publication of FI885361A publication Critical patent/FI885361A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
FI885361A 1987-11-23 1988-11-18 Laekemedel-monoklonala antikroppskonjugat. FI885361A (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/124,313 US4952394A (en) 1987-11-23 1987-11-23 Drug-monoclonal antibody conjugates

Publications (2)

Publication Number Publication Date
FI885361A0 true FI885361A0 (fi) 1988-11-18
FI885361A FI885361A (fi) 1989-05-24

Family

ID=22414122

Family Applications (1)

Application Number Title Priority Date Filing Date
FI885361A FI885361A (fi) 1987-11-23 1988-11-18 Laekemedel-monoklonala antikroppskonjugat.

Country Status (16)

Country Link
US (1) US4952394A (fi)
EP (1) EP0317957B1 (fi)
JP (1) JPH02111731A (fi)
KR (1) KR910005887B1 (fi)
AT (1) ATE81986T1 (fi)
AU (1) AU617380B2 (fi)
CA (1) CA1303524C (fi)
DE (1) DE3875700T2 (fi)
DK (1) DK651088A (fi)
FI (1) FI885361A (fi)
GR (1) GR3006211T3 (fi)
IL (1) IL88428A0 (fi)
NO (1) NO169958C (fi)
NZ (1) NZ226955A (fi)
PT (1) PT89062B (fi)
ZA (1) ZA886811B (fi)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149782A (en) * 1988-08-19 1992-09-22 Tanox Biosystems, Inc. Molecular conjugates containing cell membrane-blending agents
US5171563A (en) * 1988-09-30 1992-12-15 Neorx Corporation Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
US5155210A (en) * 1990-09-11 1992-10-13 Brunswick Corporation Methods of conjugating actinomycin d
AU8730691A (en) * 1990-09-28 1992-04-28 Neorx Corporation Polymeric carriers for release of covalently linked agents
US5776458A (en) * 1990-12-05 1998-07-07 Pharmacia & Upjohn S.P.A. Anthracycline-conjugates
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
AU701529B2 (en) * 1994-04-05 1999-01-28 Purdue Research Foundation NADH oxidase as a target in diagnosis and therapy
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
AU4907897A (en) 1996-10-11 1998-05-11 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US6299860B1 (en) * 1998-10-15 2001-10-09 Fluoro Probe, Inc. Method for viewing diseased tissue located within a body cavity
US6652836B2 (en) 1998-10-15 2003-11-25 Fluoroprobe, Inc. Method for viewing tumor tissue located within a body cavity
US7238368B2 (en) 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US7112337B2 (en) 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
EP1173221A2 (en) * 1999-04-23 2002-01-23 Alza Corporation Releasable linkage and compositions containing same
ATE340592T1 (de) * 1999-04-23 2006-10-15 Alza Corp Konjugate enthaltend eine spaltbare bindung zur anwendung in einem liposom
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
CN1110322C (zh) * 1999-07-21 2003-06-04 中国医学科学院医药生物技术研究所 单克隆抗体Fab'－平阳霉素偶联物及其抗肿瘤作用
WO2001062968A2 (en) * 2000-02-25 2001-08-30 General Atomics Mutant nucleic binding enzymes and use thereof in diagnostic, detection and purification methods
AU2001250898A1 (en) * 2000-03-17 2001-10-03 The Salk Institute For Biological Studies Compositions associated with complex formation
US6610504B1 (en) 2000-04-10 2003-08-26 General Atomics Methods of determining SAM-dependent methyltransferase activity using a mutant SAH hydrolase
EP1282714A2 (en) * 2000-05-10 2003-02-12 Bristol-Myers Squibb Company Modified inosine 5'-monophosphate dehydrogenase polypeptides and uses thereof
EP1355672A2 (en) 2000-12-01 2003-10-29 Cell Works Inc. Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP1392359B2 (en) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
MXPA03011094A (es) 2001-05-31 2004-12-06 Medarex Inc Citotoxinas, profarmacos, ligadores, y estabilizadores utiles para ello.
US7053188B2 (en) 2002-02-22 2006-05-30 Purdue Research Foundation Monoclonal antibodies specific for neoplasia-specific NADH:disulfide reductase
US7384760B2 (en) * 2004-04-30 2008-06-10 General Atomics Methods for assaying inhibitors of S-adenosylhomocysteine (SAH) hydrolase and S-adenosylmethionine (SAM)-dependent methyltransferase
US7517903B2 (en) * 2004-05-19 2009-04-14 Medarex, Inc. Cytotoxic compounds and conjugates
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
US7541330B2 (en) * 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
RU2007110846A (ru) * 2004-08-26 2008-10-10 Николас Пайрамал Индия Лимитед (In) Пролекарства, включающие новые биодеградируемые линкеры
AU2006214031A1 (en) * 2005-02-18 2006-08-24 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen (PSMA)
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
BRPI0617546A2 (pt) * 2005-09-26 2011-07-26 Medarex Inc conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto
PL1940789T3 (pl) 2005-10-26 2012-04-30 Squibb & Sons Llc Metody i związki do otrzymywania analogów cc-1065
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
CN101616911A (zh) * 2007-02-21 2009-12-30 梅达莱克斯公司 具有单个氨基酸的化学连接物及其偶联物
US9023356B2 (en) 2007-03-15 2015-05-05 Ludwig Institute For Cancer Research Ltd Treatment method using EGFR antibodies and SRC inhibitors and related formulations
US8956825B2 (en) 2007-05-24 2015-02-17 The United States Of America As Represented By The Department Of Veterans Affairs Intranuclear protein transduction through a nucleoside salvage pathway
ES2609915T3 (es) 2007-08-14 2017-04-25 Ludwig Institute For Cancer Research Ltd. Anticuerpo monoclonal 175 direccionado al receptor de EGF y derivados y usos del mismo
JP6035009B2 (ja) 2007-08-22 2016-11-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
WO2009039207A1 (en) * 2007-09-19 2009-03-26 Oncofluor, Inc. Method for imaging and treating organs and tissues
CN102143970B (zh) 2008-05-27 2017-02-08 健赞股份有限公司 α‑促黑素细胞激素的肽类似物
KR101413480B1 (ko) 2008-12-05 2014-07-10 아브락시스 바이오사이언스, 엘엘씨 Ｓｐａｒｃ 결합 펩티드와 이들의 용도
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
RU2011138951A (ru) 2009-02-23 2013-03-27 Сайтомкс Терапьютикс, Инк. Пропротеины и способы их применения
EP2438090B1 (en) 2009-05-28 2016-07-06 The United States Government as Represented by the Department of Veterans Affairs Amino acid sequences which enhance peptide conjugate solubility
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
GB201012410D0 (en) 2010-07-23 2010-09-08 Medical Res Council Intracellular immunity
RU2606016C2 (ru) 2011-01-14 2017-01-10 Редвуд Байосайнс, Инк. Меченые альдегидом полипептиды иммуноглобулина и способы их применения
GB201202268D0 (en) 2012-02-09 2012-03-28 Medical Res Council Intracellular immunity
AU2012395148B2 (en) 2012-11-24 2016-10-27 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
WO2015127685A1 (en) 2014-02-28 2015-09-03 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
US11053302B2 (en) 2014-11-05 2021-07-06 Nanyang Technological University Stabilized and autonomous antibody VH domain
CA2991973C (en) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CN109071634A (zh) 2016-04-26 2018-12-21 R.P.谢勒技术有限责任公司 抗体偶联物及其制备和使用方法
US20190330317A1 (en) 2016-06-15 2019-10-31 Yale University Anti-guanosine antibody as a molecular delivery vehicle
JP2019518040A (ja) 2016-06-15 2019-06-27 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 腫瘍に対して標的化されるナノキャリアの抗体媒介性自触反応的送達
KR102459469B1 (ko) 2016-11-14 2022-10-26 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
US20210054102A1 (en) 2018-02-01 2021-02-25 Yale University Compositions and methods for enhancing nuclear translocation
EP4182475A2 (en) 2020-07-17 2023-05-24 Onena Medicines S.L. Antibodies against lefty proteins
EP4079327A1 (en) * 2021-04-22 2022-10-26 Centaurus Polytherapeutics Payloads for drug-conjugates and their use for treating cancer
WO2023010060A2 (en) 2021-07-27 2023-02-02 Novab, Inc. Engineered vlrb antibodies with immune effector functions
WO2023056450A1 (en) 2021-09-30 2023-04-06 Yale University Compositions and methods for the treatment of autosomal dominant polycystic kidney disease and other diseases having upregulated mtor activity
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
WO2024064752A2 (en) 2022-09-20 2024-03-28 Yale University Compositions of wet adhesives derived from vibrio cholerae biofilm adhesins and methods thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003792A (en) * 1967-07-01 1977-01-18 Miles Laboratories, Inc. Conjugates of acid polysaccharides and complex organic substances
EP0083367A1 (en) * 1981-07-02 1983-07-13 WALTON, Alan G. Glycosaminoglycan drug complexes
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
JPH0651643B2 (ja) * 1983-01-19 1994-07-06 帝人株式会社 殺細胞性修飾免疫グロブリン及びその製造方法
US4625014A (en) * 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
EP0224987B1 (en) * 1985-11-29 1992-04-15 Biomatrix, Inc. Drug delivery systems based on hyaluronan, derivatives thereof and their salts and method of producing same
GB8603537D0 (en) * 1986-02-13 1986-03-19 Parker D Conjugate compound

Also Published As

Publication number Publication date
AU617380B2 (en) 1991-11-28
PT89062B (pt) 1993-07-30
IL88428A0 (en) 1989-06-30
ATE81986T1 (de) 1992-11-15
EP0317957B1 (en) 1992-11-04
FI885361A (fi) 1989-05-24
NO885199D0 (no) 1988-11-22
DK651088D0 (da) 1988-11-22
JPH02111731A (ja) 1990-04-24
PT89062A (pt) 1989-11-30
NZ226955A (en) 1991-11-26
NO885199L (no) 1989-05-24
US4952394A (en) 1990-08-28
ZA886811B (en) 1989-07-26
DK651088A (da) 1989-05-24
EP0317957A3 (en) 1989-07-05
DE3875700T2 (de) 1993-03-18
CA1303524C (en) 1992-06-16
NO169958B (no) 1992-05-18
GR3006211T3 (fi) 1993-06-21
AU2582488A (en) 1989-05-25
KR910005887B1 (ko) 1991-08-06
EP0317957A2 (en) 1989-05-31
NO169958C (no) 1992-08-26
KR890007724A (ko) 1989-07-05
DE3875700D1 (de) 1992-12-10

Similar Documents

Publication Publication Date Title
FI885361A (fi) Laekemedel-monoklonala antikroppskonjugat.
DK1030670T3 (da) Anvendelse af vitamin D-derivater til forstærkning af virkningen af cytotoksiske midler
PT90049A (pt) Forma de dosagem para administrar um medicamento para terapia humana
PT947222E (pt) Metodo de activacao de agentes fotossensiveis
DE69128791D1 (de) Modifizierte antikörper mit kontrollierter clearance-zeit
ATE105484T1 (de) Aminderivate von folsaeure analogen.
DK0412554T3 (da) Sustained-release-præparat til administration i hjernen
IT1093390B (it) Impianto di regolazione dell'iniezione del combustibile di motori endotermici
ATE87318T1 (de) Ricin-antikoerper-konjugate.
DE68922035D1 (de) Glyzerin-Derivat und dessen pharmazeutische Verwendung.
SE7708622L (sv) 2-bensyl-perhydroazepiner, sett for framstellning derav och lekemedel, innehallande dem
ES2079345T3 (es) Administracion subcutanea de gonadotropina corionica humana.
IT8026232A0 (it) Composizioni farmaceutiche. derivato dell'alfa-mercapto propionilglicina ad attivita'terapeutica, procedimento per lasua preparazione e relative
ATE499115T1 (de) Antikörper verwiesene enzymprodrugtherapie mit glukuronidase
ATE66602T1 (de) Verwendung von nitrophenylgruppen zur stimulierung der inkorporationsfaehigkeit eines arzneimittels in die empfindlichen wirtszellen.
IT8722423A0 (it) Composti eterociclici alifatici nsostituiti atti a facilitare il passaggio di sostanze attive attraverso le barrierefisiologiche.
IT8019080A0 (it) Derivati dell'indometacina adattivita' terapeutica e procedimenti per ottenerli.
ES464595A1 (es) Procedimiento de preparacion de nuevos derivados de fenotia-zina.

Legal Events

Date Code Title Description
FD Application lapsed
MM Patent lapsed

Owner name: BRISTOL-MYERS SQUIBB COMPANY